Targeting a specific mechanism to improve treatment for acute graft-versus-host disease.
Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-11085950
This study is exploring a new way to help people with acute graft-versus-host disease (aGVHD) after stem cell transplants by using special compounds that can calm down overactive immune cells, aiming to make treatment safer and more effective for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11085950 on ClinicalTrials.gov |
What this research studies
This research investigates a new approach to treat acute graft-versus-host disease (aGVHD), a serious condition that can occur after stem cell transplants. It focuses on inhibiting Bromodomain and Extraterminal (BET) domains to regulate inflammatory responses in T cells, which are often overactive in aGVHD. By using novel compounds that have better tolerability than traditional treatments, the research aims to reduce harmful T cell activity and improve patient outcomes. The study will involve both clinical and translational methods to evaluate the effectiveness of these new treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have undergone allogeneic stem cell transplantation and are experiencing acute graft-versus-host disease that does not respond to standard steroid treatments.
Not a fit: Patients who have not undergone stem cell transplantation or those whose aGVHD is responsive to corticosteroid therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients suffering from steroid-refractory acute graft-versus-host disease.
How similar studies have performed: Previous research has shown promise in targeting epigenetic regulation for inflammatory conditions, suggesting potential success for this novel approach.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHOE, HANNAH — OHIO STATE UNIVERSITY
- Study coordinator: CHOE, HANNAH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Graft Versus Host Disease, acute graft vs host disease, acute graft vs. host disease